Abstract
Nivolumab, a human IgG4 programmed death (PD)-1 immune checkpoint inhibitor antibody, is approved in Israel and other parts of the world, for the treatment of patients with advanced non-small cell lung cancer (NSCLC) and disease progression during or after platinum-based chemotherapy, without a need to determine the level of PD-L1 expression in the tumor. In this series, we retrospectively analyzed the results of treating patients with NSCLC by nivolumab. This series represents real life results, out of a clinical trial, with broad inclusion criteria.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
